{"id":27270,"date":"2025-04-07T12:45:48","date_gmt":"2025-04-07T12:45:48","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/it\/?page_id=27270"},"modified":"2026-05-06T07:37:51","modified_gmt":"2026-05-06T07:37:51","slug":"sclerosi-multipla","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/","title":{"rendered":"Sclerosi multipla Briumvi"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"27270\" class=\"elementor elementor-27270\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-fdd049e elementor-section-full_width elementor-section-height-full elementor-section-content-space-between elementor-section-height-default elementor-section-items-middle\" data-id=\"fdd049e\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-af1ebaa\" data-id=\"af1ebaa\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-7c34519 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7c34519\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-a3b3d84\" data-id=\"a3b3d84\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d8f927d elementor-widget elementor-widget-html\" data-id=\"d8f927d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\tPer i tuoi pazienti che vivono<br>\r\nla sclerosi multipla\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c0a99b6 elementor-widget__width-initial elementor-absolute elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"c0a99b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_position&quot;:&quot;absolute&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Riduzione mediana del 97% della conta delle cellule B CD19+ rispetto ai valori basali dopo la prima infusione<sup>1<\/sup><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bced2a5 elementor-widget__width-initial elementor-absolute elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"bced2a5\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_position&quot;:&quot;absolute&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tARR 0,08 (ULTIMATE I) e 0,09\n(ULTIMATE II) rispetto a teriflunomide\n(ARR 0,19 e 0,18, rispettivamente)<sup>1,2<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-992dbfd\" data-id=\"992dbfd\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ebba4a6 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-image\" data-id=\"ebba4a6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png\" title=\"\" alt=\"\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-7e0aadd elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7e0aadd\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-534d167\" data-id=\"534d167\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1a342e0 elementor-widget elementor-widget-html\" data-id=\"1a342e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\r\n\r\nLa prima terapia anti-CD20 per la sclerosi multipla<sup>2<\/sup><\/sup><br> che raggiunge un ARR <0,1 in due studi clinici di fase 3\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a150cd8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a150cd8\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7d86bcc\" data-id=\"7d86bcc\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-607bb0f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"607bb0f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-c1cc15b\" data-id=\"c1cc15b\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2e47a96 elementor-widget elementor-widget-text-editor\" data-id=\"2e47a96\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Design glicoingegnerizzato<\/h3><p>BRIUMVI\u00ae \u00e8 un anticorpo citolitico diretto contro il CD20, progettato per un&#8217;efficace deplezione delle cellule B.<sup>1,2<\/sup><br \/>Vedere il profilo farmacologico di BRIUMVI\u00ae<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b1182c8 elementor-widget elementor-widget-button\" data-id=\"b1182c8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Profilo farmacologico di Briumvi<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-a3d2623\" data-id=\"a3d2623\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6a93e28 elementor-widget elementor-widget-text-editor\" data-id=\"6a93e28\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Somministrazione semplificata<\/h3><p>BRIUMVI\u00ae viene somministrato come infusione di un&#8217;ora due volte all&#8217;anno ogni 24 settimane <sup>1,3,4,5,a <\/sup>dopo la prima infusione. Negli studi clinici, il 95% delle infusioni di BRIUMVI \u00e8 stato somministrato senza interruzioni.<sup>3<\/sup><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e97a9d4 elementor-widget elementor-widget-button\" data-id=\"e97a9d4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/dosaggio-e-somministrazione\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Dosaggio e somministrazione<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-9d2e154 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9d2e154\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-0b88f45\" data-id=\"0b88f45\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d490c93 elementor-widget elementor-widget-text-editor\" data-id=\"d490c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Efficacia dimostrata<\/h3>\n<p>Nei clinical trials, Briumvi riduce significativamente il numero di recidive nelle lesioni in T1 e T2 rispetto a teriflunomide. Briumvi \u00e8 il primo anticorpo monoclonale indicato in SM a raggiungere un valore di ARR&lt;0,1 in due trials clinici di fase 3<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-37271f5 elementor-widget elementor-widget-button\" data-id=\"37271f5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/efficacia-provata\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Efficacia<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-6f26b02\" data-id=\"6f26b02\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c8e9471 elementor-widget elementor-widget-text-editor\" data-id=\"c8e9471\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Profilo di sicurezza nel range in linea con quello di teriflunomide di una terapia anti-CD20<\/h3><p>I tassi complessivi di infezione in entrambi i gruppi erano simili per i pazienti trattati con BRIUMVI\u00ae (55,8%) e con teriflunomide (54,4%). Le infezioni erano prevalentemente di gravit\u00e0 lieve o moderata.<sup>1<\/sup><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-52b8c26 elementor-widget elementor-widget-button\" data-id=\"52b8c26\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Sicurezza<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-2ff9ade elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2ff9ade\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-0b015c6\" data-id=\"0b015c6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3891e0 elementor-align-justify elementor-widget__width-auto elementor-widget-tablet__width-initial elementor-widget elementor-widget-button\" data-id=\"e3891e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Disegno dello studio<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-880d9b1 elementor-align-justify elementor-widget__width-auto elementor-widget-tablet__width-initial elementor-widget elementor-widget-button\" data-id=\"880d9b1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/iniziare\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Per iniziare<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-004939f elementor-align-justify elementor-widget__width-auto elementor-widget-tablet__width-initial elementor-widget elementor-widget-button\" data-id=\"004939f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.neuraxpharm.com\/it\/contatto\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contatti<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ec4302 elementor-align-justify elementor-widget__width-auto elementor-widget-tablet__width-initial elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-button\" data-id=\"7ec4302\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/develop.neuraxpharm.com\/it\/briumvi\/supporto-al-paziente\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Supporto ai pazienti<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-6e6cfc2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6e6cfc2\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-82f06a4\" data-id=\"82f06a4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7cf9cd5 elementor-widget elementor-widget-text-editor\" data-id=\"7cf9cd5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>    }<\/p>\n<p>    .sup-text {<br \/>      font-size: smaller;<br \/>      vertical-align: super;<br \/>    }<br \/>  <\/style>\n\n<span class=\"reference-text\"><sup>a<\/sup>Dopo la dose iniziale. L&#8217;infusione del 1\u00b0 giorno \u00e8 di 150 mg in 4 ore; l&#8217;infusione del 15\u00b0 giorno \u00e8 di 450 mg in 1 ora; le infusioni successive sono di 450 mg in 1 ora, ogni 24 settimane. La durata dell&#8217;infusione pu\u00f2 essere pi\u00f9 lunga se l&#8217;infusione viene interrotta o rallentata.<span class=\"sup-text\">1<\/span><\/span>\n<br>\n<span class=\"reference-text\"><sup>b<\/sup>ARR per BRIUMVI\u00ae osservato negli studi ULTIMATE I e II di fase 3.2 I confronti tra gli studi non sono appropriati a causa della variazione delle popolazioni di pazienti inclusi nei diversi studi. ARR = Tasso di ricaduta annualizzato<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-89991ce elementor-widget elementor-widget-text-editor\" data-id=\"89991ce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><style>\n    .reference-list {<br \/>\n        display: flex;<br \/>\n        flex-direction: column;<br \/>\n        gap: 1em;<br \/>\n    }<\/p>\n<p>    .reference-item {<br \/>\n        display: flex;<br \/>\n        align-items: flex-start;<br \/>\n    }<\/p>\n<p>    .reference-number {<br \/>\n        font-size: smaller;<br \/>\n        margin-right: 5px;<br \/>\n        vertical-align: super;<br \/>\n    }<\/p>\n<p>    .reference-text {<br \/>\n        text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>\n    }<\/p>\n<p>    .sup-text {<br \/>\n        font-size: 9px;<br \/>\n        vertical-align: super;<br \/>\n        font-family: Poppins, sans-serif;<br \/>\n    }<\/p>\n<p>    .no-letter-spacing {<br \/>\n        letter-spacing: 0px;<br \/>\n    }<br \/>\n<\/style><\/p><div class=\"reference-list\"><div class=\"reference-item\"><span class=\"reference-text\"><br \/><strong>Riferimenti<\/strong><br \/><\/span><\/div><div class=\"reference-item\"><span class=\"reference-text\"><sup>1<\/sup>Neuraxpharm Pharmaceuticals S.L. BRIUMVI\u00ae, INN-ublituximab. Summary of product characteristics. European Medicines Agency.<br \/>Disponibile su: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/BRIUMVI-epar-product-information_en.pdf (consultato il 17 novembre 2023).<br \/><\/span><\/div><div class=\"reference-item\"><span class=\"reference-text\"><sup>2<\/sup>Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.<br \/><em>N Engl J Med.<\/em> 2022;387(8):704-714. doi:10.1056\/NEJMoa2201904.<br \/><\/span><\/div><div class=\"reference-item\"><span class=\"reference-text\"><sup>3<\/sup>Fox EJ, Steinman L, Hartung H-P, et al. Infusion-related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): post hoc analyses from the phase 3 ULTIMATE I and II studies.<br \/>Presentato al: 2022 American Academy of Neurology (AAN) Annual Meeting; Aprile 2-7, 24-26, 2022; Seattle, WA.<br \/><\/span><\/div><div class=\"reference-item\"><span class=\"reference-text\"><sup>4<\/sup>Novartis Ireland Limited. Kesimpta, INN-ofatumumab. Summary of product characteristics. European Medicines Agency.<br \/>Disponibile su: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf (consultato il 17 novembre 2023).<br \/><\/span><\/div><div class=\"reference-item\"><span class=\"reference-text\"><sup>5<\/sup>Roche Registration GmbH. Ocrevus, INN-ocrelizumab. Summary of product characteristics. European Medicines Agency.<br \/>Disponibile su: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf (consultato il 17 novembre 2023).<br \/><\/span><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9166282 elementor-section-content-middle elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9166282\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8dd8ef7\" data-id=\"8dd8ef7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-e7b965b elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"e7b965b\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-5d60cb5\" data-id=\"5d60cb5\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a86749e elementor-widget elementor-widget-heading\" data-id=\"a86749e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Cerchi una <span>risorsa educativa<\/span> su BRIUMVI\u00ae da fornire ai tuoi pazienti?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f3b024f elementor-align-left elementor-widget elementor-widget-button\" data-id=\"f3b024f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-xl\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Scarica il foglietto illustrativo di BRIUMVI\u00ae.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-281aba4\" data-id=\"281aba4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e754c2e elementor-widget elementor-widget-image\" data-id=\"e754c2e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1709\" height=\"1139\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img.jpg\" class=\"attachment-full size-full wp-image-28933\" alt=\"\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img.jpg 1709w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img-300x200.jpg 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img-1024x682.jpg 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img-768x512.jpg 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img-1536x1024.jpg 1536w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063157\/briumvi-home-img-600x400.jpg 600w\" sizes=\"(max-width: 1709px) 100vw, 1709px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ac676ea elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ac676ea\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-304b453\" data-id=\"304b453\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-98d6fe6 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"98d6fe6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/8574878.fs1.hubspotusercontent-na1.net\/hubfs\/8574878\/BRIUMVI\/2026\/SMPC\/RIASSUNTO%20Briumvi%20September3rd2025%20COLOR_Print%20pages.pdf\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Consulta il riassunto delle carratteristiche del prodotto<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4d098b4 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"4d098b4\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-476a048\" data-id=\"476a048\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-d3d5423 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"d3d5423\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-6af1a24\" data-id=\"6af1a24\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-655a66f elementor-align-center elementor-widget elementor-widget-button\" data-id=\"655a66f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/develop.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2025\/04\/riassunto-briumvi-jan16th2025.pdf\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Consultate il SmPC qui<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Per i tuoi pazienti che vivono la sclerosi multipla Riduzione mediana del 97% della conta delle cellule B CD19+ rispetto ai valori basali dopo la prima infusione1 ARR 0,08 (ULTIMATE I) e 0,09 (ULTIMATE II) rispetto a teriflunomide (ARR 0,19 e 0,18, rispettivamente)1,2 La prima terapia anti-CD20 per la sclerosi multipla2 che raggiunge un ARR<\/p>\n","protected":false},"author":2493,"featured_media":0,"parent":2667,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-27270","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sclerosi multipla Briumvi - Neuraxpharm Italia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sclerosi multipla Briumvi\" \/>\n<meta property=\"og:description\" content=\"Per i tuoi pazienti che vivono la sclerosi multipla Riduzione mediana del 97% della conta delle cellule B CD19+ rispetto ai valori basali dopo la prima infusione1 ARR 0,08 (ULTIMATE I) e 0,09 (ULTIMATE II) rispetto a teriflunomide (ARR 0,19 e 0,18, rispettivamente)1,2 La prima terapia anti-CD20 per la sclerosi multipla2 che raggiunge un ARR\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T07:37:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\",\"name\":\"Sclerosi multipla Briumvi - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/plugins\\\/elementor\\\/assets\\\/images\\\/placeholder.png\",\"datePublished\":\"2025-04-07T12:45:48+00:00\",\"dateModified\":\"2026-05-06T07:37:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/plugins\\\/elementor\\\/assets\\\/images\\\/placeholder.png\",\"contentUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/plugins\\\/elementor\\\/assets\\\/images\\\/placeholder.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portafoglio\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sclerosi multipla Briumvi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sclerosi multipla Briumvi - Neuraxpharm Italia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla","og_locale":"it_IT","og_type":"article","og_title":"Sclerosi multipla Briumvi","og_description":"Per i tuoi pazienti che vivono la sclerosi multipla Riduzione mediana del 97% della conta delle cellule B CD19+ rispetto ai valori basali dopo la prima infusione1 ARR 0,08 (ULTIMATE I) e 0,09 (ULTIMATE II) rispetto a teriflunomide (ARR 0,19 e 0,18, rispettivamente)1,2 La prima terapia anti-CD20 per la sclerosi multipla2 che raggiunge un ARR","og_url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/","og_site_name":"Neuraxpharm Italia","article_modified_time":"2026-05-06T07:37:51+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/","url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/","name":"Sclerosi multipla Briumvi - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png","datePublished":"2025-04-07T12:45:48+00:00","dateModified":"2026-05-06T07:37:51+00:00","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/#primaryimage","url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png","contentUrl":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/plugins\/elementor\/assets\/images\/placeholder.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portafoglio","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/"},{"@type":"ListItem","position":2,"name":"Sclerosi multipla Briumvi"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/users\/2493"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/comments?post=27270"}],"version-history":[{"count":35,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270\/revisions"}],"predecessor-version":[{"id":29043,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270\/revisions\/29043"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/2667"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=27270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}